MoonLake Immunotherapeutics reported Week 40 results from its twin Phase 3 VELA trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing continued efficacy gains beyond the 16-week primary endpoint and no new safety signals. Across 838 patients, 62% of those treated achieved HiSCR75 and up to 32% reached HiSCR100 at Week 40, with up to 77% hitting IHS4-55 and as many as 25% meeting a stringent composite of inflammatory remission. Patient-reported outcomes improved meaningfully, including pain, function, mood, and quality of life metrics. Following the Week 16 readout, placebo arms crossed to active treatment, and all patients are now through Week 40, with 52-week data expected in the second quarter of 2026 ahead of a planned HS BLA submission in the second half.
The strategic question is whether these long-term data carve out a durable, defensible advantage in an HS market already reshaped by IL-17 entrants. By designing VELA around the higher HiSCR75 threshold and touting deep lesion control and remission signals by Week 40, MoonLake is aiming to reset the efficacy bar. If the 52-week dataset corroborates these trajectories and supports consistent benefit on pain and quality of life, sonelokimab could mount a credible bid for earlier-line use and potentially compress the role of legacy TNF blockade in HS.
Timing and stakeholders matter. Dermatologists have been seeking agents that deliver sustained control of draining tunnels and nodules, not just short-term flare suppression. The Week 40 signal across hallmark lesions and pain reduction could prompt algorithm shifts toward earlier IL-17 pathway inhibition, particularly in patients with refractory tunnels where surgical interventions loom. Payers will scrutinize durability, discontinuation, and healthcare utilization impacts. HS is prevalent, progressive, and costly, with high procedure and infection burdens; a therapy that reduces flares, pain, and surgeries at scale changes the budget calculus. However, access will hinge on comparative effectiveness versus approved IL-17 agents at one year, clarity on “as observed” analyses in a switch design, and robust real-world evidence to validate quality-of-life gains and productivity benefits. For patients, the potential to move a meaningful proportion into high-threshold responses and even remission would be transformative if replicated at 52 weeks and beyond.
Commercially, MoonLake is positioning a differentiated IL-17A/F nanobody against entrenched brands. The company’s emphasis on higher clinical thresholds aligns with a broader regulatory and payer drift toward more stringent endpoints and patient-reported outcomes. If sonelokimab sustains performance into 52 weeks and secures HS approval on that basis, cross-indication expansion in psoriatic arthritis could enable portfolio contracting and shared care pathways across dermatology and rheumatology, a tactic that incumbents have used effectively. The Week 40 readout also reinforces an industry trend: late-stage biotech contenders are competing not just on mechanism, but on depth of response, remission language, and durability—metrics that resonate with clinical committees and HTA bodies as biologics become crowded classes.
The next data drop will decide whether the current momentum converts into labeling and access advantages. Can MoonLake deliver 52-week, intention-to-treat results that hold their edge versus class benchmarks, translate PRO gains into payer-relevant outcomes, and leverage upcoming psoriatic arthritis readouts to negotiate for earlier-line positioning in HS? The answer will determine if sonelokimab becomes another entrant in a competitive aisle—or the product that rewrites the HS treatment ladder.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
